 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Spikevax (elasomeran) / Moderna
Journal: Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters. (Pubmed Central) - Apr 6, 2024
Notably, the strength of antibody responses after booster vaccination differed by the exact vaccine formulation, with variant-updated mRNA-1273.211 and mRNA-1273.617.2 booster formulations inducing significantly stronger S-specific signals than a mRNA-1273 booster. Overall, these results identify key S-specific epitopes targeted by antibodies induced by mRNA-1273 primary and variant-updated booster vaccination.
- | Phase classification: COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (clinicaltrials.gov) - Mar 12, 2024
P2, N=1270, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Overall, these results identify key S-specific epitopes targeted by antibodies induced by mRNA-1273 primary and variant-updated booster vaccination. Phase classification: P1/2 --> P2
- | Trial completion, Trial completion date, Trial primary completion date: COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (clinicaltrials.gov) - Jan 5, 2024
P1/2, N=1270, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P1/2 --> P2 Active, not recruiting --> Completed | Trial completion date: Oct 2024 --> Nov 2023 | Trial primary completion date: Oct 2024 --> Nov 2023
- ||||||| Trial completion: A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (clinicaltrials.gov) - Dec 21, 2023
P2/3, N=5404, Completed, Sponsor: ModernaTX, Inc.
Active, not recruiting --> Completed | Trial completion date: Oct 2024 --> Nov 2023 | Trial primary completion date: Oct 2024 --> Nov 2023 Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date: COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (clinicaltrials.gov) - Jul 21, 2023
P1/2, N=1270, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial completion date: Mar 2026 --> Oct 2024 | Trial primary completion date: Mar 2026 --> Oct 2024
- |||| Trial completion date, Trial primary completion date: A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (clinicaltrials.gov) - May 24, 2023
P2/3, N=5404, Active, not recruiting, Sponsor: ModernaTX, Inc.
Trial completion date: Mar 2026 --> Oct 2024 | Trial primary completion date: Mar 2026 --> Oct 2024 Trial completion date: Apr 2023 --> Nov 2023 | Trial primary completion date: Apr 2023 --> Nov 2023
- | Enrollment closed: COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (clinicaltrials.gov) - Nov 21, 2022
P1/2, N=1270, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Apr 2023 --> Nov 2023 | Trial primary completion date: Apr 2023 --> Nov 2023 Recruiting --> Active, not recruiting
- | Enrollment open, Enrollment change: COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (clinicaltrials.gov) - Oct 10, 2022
P1/2, N=1500, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting | N=1068 --> 1500
- | Enrollment closed: COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (clinicaltrials.gov) - Jul 5, 2022
P1/2, N=1068, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Recruiting | N=1068 --> 1500 Recruiting --> Active, not recruiting
- ||||| Enrollment closed: A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (clinicaltrials.gov) - May 2, 2022
P2/3, N=4658, Active, not recruiting, Sponsor: ModernaTX, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Enrollment open: COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (clinicaltrials.gov) - Apr 6, 2022
P1/2, N=1500, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | New P1/2 trial: COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (clinicaltrials.gov) - Mar 21, 2022
P1/2, N=1500, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- ||||| Enrollment change, Trial completion date, Trial primary completion date: A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (clinicaltrials.gov) - Mar 2, 2022
P2/3, N=4720, Recruiting, Sponsor: ModernaTX, Inc.
Not yet recruiting --> Recruiting N=3620 --> 4720 | Trial completion date: Nov 2022 --> Mar 2023 | Trial primary completion date: Jun 2022 --> Mar 2023
- |||||| Enrollment open, Enrollment change: A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (clinicaltrials.gov) - Oct 31, 2021
P2/3, N=3620, Recruiting, Sponsor: ModernaTX, Inc.
N=3620 --> 4720 | Trial completion date: Nov 2022 --> Mar 2023 | Trial primary completion date: Jun 2022 --> Mar 2023 Active, not recruiting --> Recruiting | N=1768 --> 3620
- ||||| Enrollment change: A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (clinicaltrials.gov) - Aug 30, 2021
P2/3, N=1768, Active, not recruiting, Sponsor: ModernaTX, Inc.
Active, not recruiting --> Recruiting | N=1768 --> 3620 N=896 --> 1768
- ||||| Enrollment change: A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (clinicaltrials.gov) - Aug 18, 2021
P2/3, N=896, Active, not recruiting, Sponsor: ModernaTX, Inc.
N=896 --> 1768 N=300 --> 896
- |||||||||| New P2/3 trial: A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants (clinicaltrials.gov) - Jun 15, 2021
P2/3, N=300, Active, not recruiting, Sponsor: ModernaTX, Inc.